Abstract. Clioquinol (CQ) is a “metal protein attenuating compound” that crosses the blood-brain barrier and binds, with high affinity, copper(II) and zinc(II), two metal ions critically involved in amyloid-β aggregation and toxicity. CQ was recently proposed for the treatment of Alzheimer’s disease, but controversial data have been reported so far concerning its real therapeutic advantages. We describe here results of chronic CQ treatment in the TgCRND8 mouse model of Alzheimer’s disease. Remarkably, based on classical behavioral tests, CQ treatment was found to reverse, to a large extent, the working memory impairments that are characteristic of this mouse model. Pairwise, a significant reduction of amyloid-β plaque burden, both in the cortex and in the hippocampus, was detected as well as an attenuation of astrogliosis. MALDI Mass Spectrometry Imaging technique revealed a specific localization of CQ in the above mentioned brain areas. Modest but significant effects on the absolute and relative brain concentrations of the three most important biometals (i.e., copper, zinc, and iron) were highlighted following CQ treatment. The pharmacological and mechanistic implications of the above findings are thoroughly discussed.

Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease / C. Grossi;S. Francese;A. Casini;M. C. Rosi;I. Luccarini;A. Fiorentini;C. Gabbiani;L. Messori;G. Moneti;F. Casamenti. - In: JOURNAL OF ALZHEIMER'S DISEASE. - ISSN 1387-2877. - ELETTRONICO. - 17:(2009), pp. 423-440. [10.3233/JAD-2009-1063]

Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.

GROSSI, CRISTINA;ROSI, MARIA CRISTINA;LUCCARINI, ILARIA;FIORENTINI, ANNA;GABBIANI, CHIARA;MESSORI, LUIGI;MONETI, GLORIANO;CASAMENTI, FIORELLA
2009

Abstract

Abstract. Clioquinol (CQ) is a “metal protein attenuating compound” that crosses the blood-brain barrier and binds, with high affinity, copper(II) and zinc(II), two metal ions critically involved in amyloid-β aggregation and toxicity. CQ was recently proposed for the treatment of Alzheimer’s disease, but controversial data have been reported so far concerning its real therapeutic advantages. We describe here results of chronic CQ treatment in the TgCRND8 mouse model of Alzheimer’s disease. Remarkably, based on classical behavioral tests, CQ treatment was found to reverse, to a large extent, the working memory impairments that are characteristic of this mouse model. Pairwise, a significant reduction of amyloid-β plaque burden, both in the cortex and in the hippocampus, was detected as well as an attenuation of astrogliosis. MALDI Mass Spectrometry Imaging technique revealed a specific localization of CQ in the above mentioned brain areas. Modest but significant effects on the absolute and relative brain concentrations of the three most important biometals (i.e., copper, zinc, and iron) were highlighted following CQ treatment. The pharmacological and mechanistic implications of the above findings are thoroughly discussed.
2009
17
423
440
C. Grossi;S. Francese;A. Casini;M. C. Rosi;I. Luccarini;A. Fiorentini;C. Gabbiani;L. Messori;G. Moneti;F. Casamenti
File in questo prodotto:
File Dimensione Formato  
Clioquinol.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 2.37 MB
Formato Adobe PDF
2.37 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/368126
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 115
  • ???jsp.display-item.citation.isi??? 105
social impact